ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Association between angiogenic features and responsiveness to faricimab in treatment-naïve neovascular age-related macular degeneration with OCT angiography.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate morphological changes in macular neovascularization (MNV) using optical coherence tomography angiography (OCTA) and identify imaging biomarkers associated with treatment responsiveness to faricimab in patients with neovascular age-related macular degeneration (nAMD).
methodsThis prospective study investigated consecutive eyes of patients with treatment-naïve nAMD who were treated with faricimab. After 3-monthly loading doses, the patients received a fixed 8-, 12-, or 16-week treatment regimen (Q8W/Q12W/Q16W) and were grouped as poor responders (Q8W/Q12W) or good responders (Q16W). Dosing interval determination depended on disease activity post-loading phase. Baseline and 14-month quantitative OCTA parameters were analyzed.
resultsForty-four eyes (pure type 1 MNV: 35 eyes, mixed type 1 and type 2 MNV: 9 eyes) were analyzed. The visual acuity (P < 0.001) and central retinal thickness (P < 0.0001) significantly improved post-faricimab treatment from baseline to Month 14. In mixed type 1 and type 2 MNV, total vessel length decreased from baseline to Month 14 (P < 0.05), whereas vessel area did not significantly change (P = 0.11). No significant changes in total vessel length or vessel area were detected in pure type 1 MNV (P = 0.23 and P = 0.30, respectively). In the subgroup of type 1 MNV, a significant decrease in endpoint density was observed only in good responders (P = 0.04), with no corresponding change in poor responders.
conclusionA fixed faricimab regimen through Month 14 was associated with improved visual and anatomical outcomes in treatment-naïve nAMD. OCTA-based vascular changes differed according to MNV type and treatment responsiveness. In pure type 1 MNV, endpoint density may be a potential OCTA-based biomarker associated with treatment responsiveness, contributing to a more personalized therapeutic approach for nAMD.
Indexed as
Identifiers
42406042What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.